Docket No.: P-204.00CON Application No. 09/963,341

Amendment Dated March 21, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-58 (Cancelled).

- 59. (Amended) A method of preparing a purified biologically active alpha 1-antitrypsin (α1-AT) preparation containing an α1- AT isomer having a pl of between 4.3 and 4.4 comprising: providing a <u>starting</u> material containing active and inactive α1- AT, <u>wherein</u> the starting material is a plasma fraction obtained from pooled human plasma; providing a hydroxyapatite substrate; passing said starting material containing α1- AT over said hydroxyapatite substrate; and eluting said purified biologically active alpha 1-antitrypsin (α1- AT) preparation containing an α1- AT isomer having a pl of betwee4.3 and 4.4
- 60. (Previously presented) The method of preparing a purified biologically active alpha 1antitrypsin (α1- AT) preparation according to claim 59, further comprising passing said material containing α1- AT over an anion exchange material.
- 61. (Previously presented) The method according to claim 59, wherein said eluting step is conducted with a buffer having a pH of between 5.5 and 8.0.
- 62. (Previously presented) The method according to claim 61, wherein said eluting step is conducted with a buffer having a pH of between 6.5 and 6.8.
- 63. (Cancelled)
- 64. (Previously presented) The method according to claim 59, wherein said starting material is an albumin-depleted plasma fraction.
- 65. (Previously presented) The method according to claim 59, wherein said starting material is Cohn V precipitate.
- 66. (Previously presented) The method according to claim 64, wherein said starting material is a pre-purified α 1- AT preparation fraction.
- 67. (Previously presented) The method according to claim 60, wherein said passing is conducted in the presence of a detergent.
- 68. (Previously presented) The method according to claim 59, wherein said hydroxyapatite is a ceramic hydroxyapatite.

Docket No.: P-204.00CON Application No. 09/963,341

Amendment Dated March 21, 2005

69. (Previously presented) The method according to claim 59, wherein said eluting is conducted with a buffer which comprises a salt having an ionic strength corresponding to 60 mM of phosphate.

- 70. (Previously presented) The method according to claim 59, wherein said eluting is conducted with a buffer which comprises a salt having an ionic strength corresponding to 40 mM of phosphate.
- 71. (Previously presented) The method according to claim 59, wherein said eluting is conducted with a buffer which comprises a salt having an ionic strength corresponding to 50 to 130 mM of phosphate.
- 72. (Previously presented) The method as set forth in claim 59, further comprising a pathogen inactivation step.
- 73. (Previously presented) The method as set forth in claim 72, wherein said pathogen inactivation step includes at least one of a solvent, a detergent or a heat treatment step.
- 74. (new) A method for purifying biologically active alpha1-AT including alpha1-AT isomers having pls of between 4.3 and 4.4 from an alpha1-AT-containing fraction which is preferably obtainable from a human plasma pool comprising:

Absorbing said acidified alpha1-AT-containing fraction onto a chromatographic anion exchanger in the presence of a detergent, and

Eluting said biologically active alpha1-AT from said chromatographic anion exchanger including alpha1-AT isomers having pls of between 4.3 and 4.4

74. (new) A method according to claim 74 in which said elution is carried out at a pH ranging between 5.5 and 8.0, preferably around 6.5-6.8